10,000, 23 ± 5 ; Ga-KE88, 9.5 ± 4.3, 4.1 ± SIAPQQ 1.4 ; AM3, 119 ± 6, 2.3 ± 0.2 ; DOTA-LTT-SS28, 9.8 ± 0.2, 2.5 ± 0.3 Ga-DOTA-FAPI-04 PET/MR in the Evaluation of Gastric Carcinomas: Comparison with 18F-FDG PET/CT. J Nucl Med. 2022 Jan;63(1):81-88. doi: 10.2967/jnumed" /> 10,000, 23 ± 5 ; Ga-KE88, 9.5 ± 4.3, 4.1 ± SIAPQQ 1.4 ; AM3, 119 ± 6, 2.3 ± 0.2 ; DOTA-LTT-SS28, 9.8 ± 0.2, 2.5 ± 0.3 Ga-DOTA-FAPI-04 PET/MR in the Evaluation of Gastric Carcinomas: Comparison with 18F-FDG PET/CT. J Nucl Med. 2022 Jan;63(1):81-88. doi: 10.2967/jnumed" /> 10,000, 23 ± 5 ; Ga-KE88, 9.5 ± 4.3, 4.1 ± SIAPQQ 1.4 ; AM3, 119 ± 6, 2.3 ± 0.2 ; DOTA-LTT-SS28, 9.8 ± 0.2, 2.5 ± 0.3 Ga-DOTA-FAPI-04 PET/MR in the Evaluation of Gastric Carcinomas: Comparison with 18F-FDG PET/CT. J Nucl Med. 2022 Jan;63(1):81-88. doi: 10.2967/jnumed" /> 10,000, 23 ± 5 ; Ga-KE88, 9.5 ± 4.3, 4.1 ± SIAPQQ 1.4 ; AM3, 119 ± 6, 2.3 ± 0.2 ; DOTA-LTT-SS28, 9.8 ± 0.2, 2.5 ± 0.3 Ga-DOTA-FAPI-04 PET/MR in the Evaluation of Gastric Carcinomas: Comparison with 18F-FDG PET/CT. J Nucl Med. 2022 Jan;63(1):81-88. doi: 10.2967/jnumed" />